<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492583</url>
  </required_header>
  <id_info>
    <org_study_id>2007-273</org_study_id>
    <nct_id>NCT00492583</nct_id>
  </id_info>
  <brief_title>Study to Investigate the Potential of Probiotics in Yogurt</brief_title>
  <acronym>SIPPY</acronym>
  <official_title>Study to Investigate the Potential of Probiotics in Yogurt</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Gerber Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the consumption of a yogurt drink containing a
      high dose of probiotics decreases absences, due to illnesses, in daycare centers for children
      between the ages of 1 and 3.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is reported that more than half of all young children attend daycare centers in the United
      States. Absences due to illnesses are costly both on an individual and societal level; these
      absences are generally due to diarrhea or upper respiratory infections.

      In the U.S., children under five years of age experience 20-35 million episodes of diarrhea
      per year. These episodes lead to 2-3.5 million physician visits (which account for 10% of all
      visits by children), more than 200,000 hospitalizations (13% of hospital admissions in
      children under five years), and 325-425 deaths annually. In 1991, the outpatient costs of
      treating diarrhea in children under age three was calculated at 0.6-1 billion dollars per
      year.

      Respiratory illness is among the leading causes of death in children under five years of age.
      Approximately 200,000 deaths in the U.S. and 3.9 million deaths worldwide are attributed to
      respiratory illnesses. Respiratory illness is also the most frequent reason for physician
      consultation, with more than 40% of all pediatric outpatient visits related to respiratory
      illness. According to a recent study, 39% of children attending daycare experienced acute
      otitis media (ear infection) and 26% reported allergies. Most notably, 10% of children
      attending daycare were admitted to the hospital due to respiratory illnesses.

      We have chosen BB-12 as the probiotic for this study as it is one of the best characterized
      probiotics with a long safety record in children, a well-proven ability to colonize the human
      intestinal tract, and demonstrated efficacy for different pediatric conditions. Furthermore,
      BB-12 is a commercially available probiotic strain that has been used in a number of feeding
      and clinical trials.

      In fact, there is a new infant formula on the market, using the identical strain we are, in
      the first commercially available probiotic infant formula available in the United States. Not
      only has BB-12 been found to survive transit through the stomach, small intestine and colon,
      but also long-term consumption of BB-12 formula at levels as high as 1 billion CFU/g (240 g
      serving) have been found to be safe.

      Our overall goal is to demonstrate that a probiotic-containing yogurt beverage can be used
      successfully as a vehicle for delivering health-enhancing probiotics; more specifically to
      determine if a yogurt drink containing Bifidobacterium lactis BB-12 at a minimum 1010 colony
      forming units (CFU)/per serving can prevent daycare absences.

      The rationale for focusing on food as a vehicle for the transmission of probiotics is that it
      has the potential to benefit children more than using probiotics in a more medicinal manner,
      such as pills or capsules. By providing an intervention in the form of a yogurt drink,
      parents are given a more convenient and simple alternative to traditional probiotic
      supplements. As yogurt is known to be a nutrient dense food, a yogurt drink is likely to be
      more appealing to both children and their parents for long-term consumption than
      pharmaceutical-like preparations. Although compliance with most medicinal regimens is around
      50%, by offering a more attractive formulation of high dose probiotics and collaborating with
      participants we believe compliance will exceed normal levels. Ultimately, by capitalizing on
      the widely accepted healthy image of yogurt and offering a simple, convenient source of
      probiotics, we believe this product has the potential to positively impact the health of
      children around the world.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Days Children Are Out of School Sick</measure>
    <time_frame>90 days</time_frame>
    <description>Outcome measure, &quot;number of days children are out of school sick&quot; was measured for the entire population</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects were provided 4 fluid ounces (112 grams) administered orally per day of placebo drink.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bifidobacterium lactis (BB-12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects were provided 4 fluid ounces (112 grams) administered orally per day of active drink.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bifidobacterium lactis (BB-12)</intervention_name>
    <description>The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).</description>
    <arm_group_label>Bifidobacterium lactis (BB-12)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 1-3

          -  attending daycare or preschool centers at least 3 days a week

          -  male or female

          -  parents must speak English or Spanish

          -  subjects or parents/legal guardians who agree to have their child refrain from
             consuming any other yogurts or foods containing probiotics for the duration of the
             study

        Exclusion Criteria:

          -  subjects with developmental delays

          -  subjects with chronic conditions such as diabetes or asthma that require daily
             medication

          -  subjects with birth weight &lt;2500 grams

          -  subjects with strawberry allergies

          -  subjects with active diarrhea

          -  subjects with congenital anomalies

          -  subjects with failure to thrive

          -  subjects with parental belief of lactose intolerance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J Merenstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Department of Family Medicine</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Merenstein DJ, Smith KH, Scriven M, Roberts RF, Sanders ME, Petterson S. The study to investigate the potential benefits of probiotics in yogurt, a patient-oriented, double-blind, cluster-randomised, placebo-controlled, clinical trial. Eur J Clin Nutr. 2010 Jul;64(7):685-91. doi: 10.1038/ejcn.2010.30. Epub 2010 Mar 10.</citation>
    <PMID>20216564</PMID>
  </results_reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <results_first_submitted>June 21, 2011</results_first_submitted>
  <results_first_submitted_qc>July 21, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2011</results_first_posted>
  <last_update_submitted>July 21, 2011</last_update_submitted>
  <last_update_submitted_qc>July 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2011</last_update_posted>
  <responsible_party>
    <name_title>Daniel Merenstein</name_title>
    <organization>Georgetown University Medical Center</organization>
  </responsible_party>
  <keyword>probiotic</keyword>
  <keyword>health</keyword>
  <keyword>bifidobacterium lactis</keyword>
  <keyword>BB-12</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
        </group>
        <group group_id="P2">
          <title>Bifidobacterium Lactis (BB-12)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
        </group>
        <group group_id="B2">
          <title>Bifidobacterium Lactis (BB-12)</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="95"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="182"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Days Children Are Out of School Sick</title>
        <description>Outcome measure, &quot;number of days children are out of school sick&quot; was measured for the entire population</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
          </group>
          <group group_id="O2">
            <title>Bifidobacterium Lactis (BB-12)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Days Children Are Out of School Sick</title>
          <description>Outcome measure, &quot;number of days children are out of school sick&quot; was measured for the entire population</description>
          <units>days per 100 person days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.51"/>
                    <measurement group_id="O2" value="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
        </group>
        <group group_id="E2">
          <title>Bifidobacterium Lactis (BB-12)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Vomiting &amp; Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis (Diaper)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel J Merenstein, MD</name_or_title>
      <organization>Georgetown University</organization>
      <phone>202-687-2745</phone>
      <email>djm23@georgetown.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

